Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

ASMB
Assembly Biosciences, Inc
stock NASDAQ

At Close
Jul 30, 2026 3:59:51 PM EDT
26.03USD+3.664%(+0.92)55,716
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-25.11)0
After-hours
Jul 27, 2026 4:00:30 PM EDT
25.91USD-0.019%(-0.01)0
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 7, 2022
05:00PM EST  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Jan 6, 2022
08:00AM EST  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will present during the HC Wainwright Virtual BIOCONNECT Conference, January 10-13, 2022.   GlobeNewswire Inc
Jan 4, 2022
08:15AM EST  Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones   Benzinga
08:00AM EST  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today outlined anticipated progress and milestones for its development pipeline in 2022.   GlobeNewswire Inc
Dec 3, 2021
05:00PM EST  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Nov 12, 2021
08:00AM EST  Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against bothpgRNA encapsidation and cccDNA formation   GlobeNewswire Inc
Nov 5, 2021
09:28AM EDT  Assembly Biosciences Q3 EPS $(0.41) Down From $(0.09) YoY, Sales $6.30M Down From $34.61M YoY   Benzinga
Nov 1, 2021
10:33AM EDT  Assembly Biosciences Abstracts Selected For Presentation At Upcoming AASLD The Liver Meeting   Benzinga
10:32AM EDT  Assembly Biosciences Abstracts Selected for Presentation at the   GlobeNewswire Inc
Oct 19, 2021
07:44AM EDT  Antios, Assembly To Evaluate Combination Of ATI-2173 And Vebicorvir In Patients With Chronic Hepatitis B Virus Infection   RTTNews
07:34AM EDT  Antios Therapeutics And Assembly Biosciences Announce Clinical Collaboration Agreement To Evaluate The Combination Of ATI-2173 And Vebicorvir In Patients With Chronic Hepatitis B Virus Infection   Benzinga
07:30AM EDT  Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection   PR Newswire
07:30AM EDT  Antios Therapeutics and Assembly Biosciences Announce Clinical   GlobeNewswire Inc
Oct 6, 2021
08:00AM EDT  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), announced participation in the below upcoming conferences focused on HBV:   GlobeNewswire Inc
Oct 1, 2021
06:04PM EDT  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Sep 13, 2021
10:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021   Benzinga
06:43AM EDT  HC Wainwright & Co. Initiates Coverage On Assembly Biosciences with Neutral Rating, Announces Price Target of $3.5   Benzinga
Sep 3, 2021
07:31AM EDT  The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself   Benzinga
Sep 2, 2021
03:18PM EDT  Mid-Afternoon Market Update: Dow Rises 90 Points; Kirkland's Shares Spike Higher   Benzinga
12:05PM EDT  Mid-Day Market Update: Crude Oil Jumps Over 2%; Assembly Biosciences Shares Plunge   Benzinga
10:18AM EDT  Mid-Morning Market Update: Markets Open Higher; Hormel Foods Cuts Earnings Outlook   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
07:03AM EDT  The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.45 A.M. EDT).   RTTNews
06:15AM EDT  William Blair Downgrades Assembly Biosciences to Market Perform   Benzinga
Sep 1, 2021
04:04PM EDT  Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158   Benzinga
04:02PM EDT  --Decision follows observation of elevatedalanine transaminase (ALT) levels in Phase 2 study--Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates   GlobeNewswire Inc
Aug 18, 2021
08:00AM EDT  Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for   GlobeNewswire Inc
Aug 5, 2021
04:44PM EDT  Assembly Biosciences Q2 EPS $(0.55) Down From $0.19 YoY   Benzinga
Aug 3, 2021
08:24AM EDT  Assembly Bio Announces Promotions Of Jason Okazaki To Chief Operating Officer And Michael Samar To Chief Financial Officer   Benzinga
08:00AM EDT  Assembly Bio Announces Key Promotions to Leadership Team   GlobeNewswire Inc
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
08:00AM EDT  Nobel Laureate Dr. Michael Houghton Appointed to Assembly   GlobeNewswire Inc
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jul 2, 2021
05:00PM EDT  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Jun 25, 2021
07:32AM EDT  The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs   Benzinga
Jun 23, 2021
08:11AM EDT  Assembly Biosciences Presents Data From HBV Core Inhibitor Programs At International Liver Congress EASL 2021   Benzinga
08:00AM EDT  Assembly Biosciences Presents Data from HBV Core Inhibitor   GlobeNewswire Inc
Jun 9, 2021
08:08AM EDT  Assembly Biosciences To Present Data From HBV Core Inhibitor Programs At The International Liver Congress EASL 2021   Benzinga
08:00AM EDT  Assembly Biosciences to Present Data from HBV Core Inhibitor   GlobeNewswire Inc
Jun 4, 2021
05:00PM EDT  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Jun 1, 2021
04:30PM EDT  Assembly Biosciences CFO Thomas J. Russo Notified Co. Of His Decision To Resign Effective June 4, 2021   Benzinga
May 27, 2021
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 24, 2021
08:00AM EDT  Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 10, 2021
06:56AM EDT  SVB Leerink Maintains Market Perform on Assembly Biosciences, Lowers Price Target to $7   Benzinga
May 7, 2021
05:00PM EDT  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
05:16PM EDT  Assembly Biosciences Q1 EPS $(0.69) Up From $(0.76) YoY   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 20, 2021
08:07AM EDT  The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex   Benzinga
Apr 14, 2021
07:51AM EDT  The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead   Benzinga
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 23, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021   Benzinga
07:05AM EDT  SVB Leerink Downgrades Assembly Biosciences to Market Perform, Lowers Price Target to $8   Benzinga
Mar 5, 2021
05:00PM EST  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Feb 26, 2021
11:52AM EST  Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection   Benzinga
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
07:38AM EST  Assembly Bipsciences, Arbutus Biopharma Initiate Phase 2 Clinical Trial Of Triple Combination Therapy For Treatment Of Chronic Hepatits B Virus   Benzinga
07:30AM EST  Trial will evaluate Assemblys core inhibitor candidate, vebicorvir, with Arbutus RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy   GlobeNewswire Inc
06:41AM EST  Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy   Benzinga
Feb 25, 2021
04:53PM EST  Assembly Biosciences Q4 Sales $79.11M Up From $15.96M YoY   Benzinga
Feb 19, 2021
08:00AM EST  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events:   GlobeNewswire Inc
Feb 5, 2021
05:00PM EST  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Dec 8, 2020
04:02PM EST  Assembly Biosciences Reports Will Wind Down Its Microbiome Program   Benzinga
04:02PM EST  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.   GlobeNewswire Inc
Dec 4, 2020
04:30PM EST  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Nov 17, 2020
08:00AM EST  Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice   GlobeNewswire Inc
Nov 16, 2020
08:13AM EST  Assembly Biosciences, Door Pharmaceuticals Sign Collaboration, Option Agreement To Develop A Novel Class Of HBV Core Protein Modulators   Benzinga
08:00AM EST  Assembly Biosciences and Door Pharmaceuticals Sign Collaboration   GlobeNewswire Inc
Nov 13, 2020
08:09AM EST  Assembly Biosciences Reports Presentation Of Data From Hep B Virus Core Inhibitor Program In Poster Sessions At American Association for the Study of Liver Diseases Meeting   Benzinga
08:00AM EST  - Data show longer-term, differentiated safety profile of vebicorvirand the importance of HBV pregenomic (pg) RNA as a key biomarker,as well as highlight Assembly Bios core inhibitor clinical pipeline-   GlobeNewswire Inc
Nov 9, 2020
10:09AM EST  Stocks Trading Near 52-Week Lows Just After Open On Monday, Nov. 9, 2020: ABCM, SOAC, KOR, BVXV, HPR, BIIB, CTRM, TTNP, ASMB   Benzinga
Nov 6, 2020
04:30PM EST  Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing   GlobeNewswire Inc
02:45PM EST  Stocks Trading Near 52-Week Lows On Friday, Nov. 6, 2020: ASRT, KBLMU, PNRG, YGMZ, APRE, UHT, LAIX, CLI, CORR, ANIP, CCOI, KBLM, NYC, UTL, PEI, TIG, EYEG, PVL, ZSAN, TTNP, NBRV, SFT, WPG, IFS, COGT, LMNL, PRFX, GBT, FNHC, ASMB, EPZM, UCL   Benzinga
02:33PM EST  Yahoo Finance Trending Stocks For Friday, Nov. 6, 2020: TTD, ACB, SQ, ROKU, CVS, NET, AYX, PLTR, SNDL, PTON, GBT, SNAP, CRON, TLRY, UBER, HEXO, MAXR, TMUS, CGC, MOGO, EA, Z, GPRO, PS, ASMB, IPOB, COTY, UI   Benzinga
02:31PM EST  Mid-Afternoon Market Update: Nasdaq Turns Positive; Global Blood Therapeutics Shares Drop Following Q3 Results   Benzinga
12:36PM EST  Mid-Day Market Update: Crude Oil Down Over 4%; Modine Manufacturing Shares Spike Higher   Benzinga
12:13PM EST  Why Assembly Biosciences Stock Is Trading Lower Today   Benzinga
10:38AM EST  Return On Capital Employed Overview: Assembly Biosciences   Benzinga
10:11AM EST  Mid-Morning Market Update: Markets Open Lower; US Economy Adds 638,000 Jobs In October   Benzinga
09:31AM EST  Benzinga's Top Upgrades, Downgrades For November 6, 2020   Benzinga
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
05:59AM EST  Jefferies Downgrades Assembly Biosciences to Hold, Announces $10 Price Target   Benzinga
Nov 5, 2020
04:11PM EST  Assembly Biosciences Q3 EPS $(0.09) Up From $(0.96) YoY, Sales $34.61M Up From $4.23M YoY   Benzinga
04:06PM EST  Assembly Biosciences Provides Update On The Ongoing Phase 2 Extension Study Of Vebicorvir In Patients With Chronic Hepatitis B Virus Infection, HBV Field Core Inhibitor Combination Study Did Not Achieve Endpoints, Vebicorvir Phase 3 On Track   Benzinga
Nov 2, 2020
08:03AM EST  Multiple Abstracts Highlighting Assembly Biosciences' Hepatitis B Core Inhibitor Development Programs Accepted For Presentation At The 2020 AASLD The Liver Meeting Digital Experience   Benzinga
08:00AM EST  - Four posters, including two late breaking, will include new clinical and preclinical data onAssembly Bioshepatitis B virus (HBV) core inhibitor portfolio   GlobeNewswire Inc
Oct 20, 2020
08:13AM EDT  Assembly Biosciences Appoints Gina Consylman To Board   RTTNews
08:00AM EDT  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors. Ms. Consylman will also serve as a member of Assemblys Audit Committee.   GlobeNewswire Inc
Oct 19, 2020
11:09AM EDT  Assembly Biosciences shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and a price target if $55 per share.   Benzinga
09:17AM EDT  Truist Securities Initiates Coverage On Assembly Biosciences with Buy Rating, Announces Price Target of $55   Benzinga
Oct 15, 2020
08:00AM EDT  Assembly Biosciences CEO Dr. John McHutchison Named Recipient of   GlobeNewswire Inc
Oct 5, 2020
07:30AM EDT  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV.   GlobeNewswire Inc
Oct 2, 2020
04:30PM EDT  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Aug 28, 2020
04:12PM EDT  Assembly Biosciences Files For Up To $300M Mixed Shelf Offering   Benzinga
06:06AM EDT  Assembly Biosciences Highlights Clinical Data from Assembly Biosciences' HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020   Benzinga
Aug 27, 2020
08:07AM EDT  Assembly Biosciences And Arbutus Biopharma Announce Clinical Collaboration Agreement To Evaluate The Combination Of Core Inhibitor ABI-H0731 With RNAi Therapeutic AB-729 In Patients With Chronic Hepatitis B Virus Infection   Benzinga
08:00AM EDT  Assembly Biosciences and Arbutus Biopharma Announce Clinical   GlobeNewswire Inc
Aug 7, 2020
04:30PM EDT  Assembly Biosciences Reports Inducement Grants Under Nasdaq   GlobeNewswire Inc
Aug 5, 2020
04:57PM EDT  Assembly Biosciences Q2 EPS $0.19 Up From $(0.72) YoY, Sales $39.38M Up From $3.08M YoY   Benzinga
Jul 20, 2020
06:39AM EDT  Assembly Biosciences Grants BeiGene Rights to Develop and Commercialize its Clinical-Stage Inhibitors for Hepatitis B in China, Assembly to Recieve $40M Cash Upfront and Up to $500M in Additional Payments   Benzinga
06:30AM EDT  -- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China --- Assembly receives $40 million upfront payment and is eligible to receiveup to $500 million in potential development, regulatory, and sales milestone payments plus royalties on product sales --- Assembly to host webcast and conference call today at 8:30 am ET --   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC